History: maternal vaccineF/aluminum phosphate adjuvant: Directing anyone interested to the Novavax.com site. On top of title page, there is a green block with Words, Respiratory Syncytial Virus., by touching that block, it will take you to clinical pipeline page. Halfway down, locate the blue page that is titled: Novavax, A History of RSV Development: 60 Years. One Goal. ( The page has 6 pictures across the top.)
Once on this page, locate picture of the RSV F Protein. Under this picture is year 2014. ( Sorry for the wild goose chase!) Note text which explains the end of Maternal Phase 2 results.
Many of you already know all about this. But many are new and searching for readily available, evidenced DD. (Note: NVAX employs different kinds of adjuvants; different, specific adjuvants, are used successfully, to best "boost " different vaccines, during or beyond trials. )
The maternal RSV trial 3 is based on the successes of trial 2, in which vaccine F was given to women of child bearing years; the vaccine F was given in a single dose, paired with the specific adjuvant, aluminum phosphate . This combination resulted in what is paraphrased here: Highest immune response observed with THIS combination; high levels of antibodies within 14 days post immunization, persisting 91 following days. (From that point, you can move on the Novavax site to the phase 3 maternal trial, involving pregnant women, and to the elderly trial).
If you want more, current DD, with well evidenced info/ research, Seeking Alpha has put out a very comprehensive review of trials and last weeks conference call, including links to relevant science journals. No reason to be persuaded by premature or inaccurate opinions and surmising from "professional " analysts, possibly setting up the recent share price drop, and short attack. At the bottom of text # 4129 is the information re: the location of the Seeking Alpha report. You decide. Just type in 4129 in the white box above. All stated here is IMO.
